ArticleJournal of orthopaedic surgery and research2025
Poly(propylene fumarate)/hydroxyapatite nanocomposite/black phosphorus nanosheet phosphate composites for enhanced bone repair.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Digital light processing bioprinting: bioink innovations and applications in tissue and organ regeneration.Journal of biological engineering · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBone defects due to trauma, infections, congenital malformations, and tumor resection remain significant health challenges. The polymethyl methacrylate (PMMA) bone cement's limitations in orthopedic applications arise from its lack of bioactivity and the toxicity of its monomers. Hydroxyapatite (HA) cement is widely used for bone reconstruction despite its inherent brittleness. Biodegradable poly(propylene fumarate) (PPF) is recognized for its exceptional performance in addressing these bone defects and providing adequate mechanical support. Black phosphorus (BP) nanosheets (BPNs) have attracted attention due to their unique puckered honeycomb lattice, broad absorption spectrum, high specific surface area, excellent antibacterial properties, and tunable bandgap. In this study, we developed a novel bone cement, PPF/HA/BP, via thermal crosslinking and conducted in vitro evaluation.
methodsPPF was synthesized using a two-step approach, whereas BPNs were produced through a liquid-phase exfoliation technique. Then, PPF/HA/BP composite materials were created using a thermal crosslinking process, followed by a thorough examination of their mechanical characteristics, compatibility with cells, osteogenic activity, and degradation properties.
resultsPPF/HA/BP bone cement was designed by optimizing formulation to possess mechanical properties comparable to bone tissue. PPF bone cement had a polymerization time of 8.16 ± 0.35 min and a temperature of 62.67 ± 0.67 °C. HA reduced polymerization time and temperature. PPF/HA/BP exhibited a polymerization time of 6.70 ± 0.10 min and a maximum temperature of 52.5 °C (P < 0.05). PPF/HA/BP enhanced the adhesion, proliferation, and mineralization of preosteoblasts on its surface and demonstrated photothermal properties. When exposed to an 808 nm laser, the bone cement's temperature rose to 50ºC. After co-culturing with MC3T3-E1 for 14 days, the PPF/HA/BP group exhibited significantly higher expression of ALP, COL I, and RUNX2 compared to the PPF and PPF/HA groups (P < 0.05). However, no statistically significant difference was observed in the expression of ALP, COL I, and RUNX2 between the PPF and positive control groups (P > 0.05).
conclusionBiodegradable PPF/HA/BP demonstrated satisfactory mechanical properties, degradation behavior, outstanding photothermal characteristics, excellent biocompatibility, and osteogenic activity. It also promoted bone regeneration by enhancing the proliferation and differentiation of MC3T3-E1 cells in vitro and upregulating the related genes' expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.